Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical… Read more
Endonovo Therapeutics Inc (ENDV) - Total Liabilities
Latest total liabilities as of June 2025: $27.84 Million USD
Based on the latest financial reports, Endonovo Therapeutics Inc (ENDV) has total liabilities worth $27.84 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Endonovo Therapeutics Inc - Total Liabilities Trend (2010–2024)
This chart illustrates how Endonovo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Endonovo Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Endonovo Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mango Capital Inc
PINK:MCAP
|
USA | $937.87 Million |
|
Biomotion Sciences Warrant
NASDAQ:SLXNW
|
USA | $4.64 Million |
|
Blue Ribbon Income Fund
TO:RBN-UN
|
Canada | CA$364.74K |
|
Seven Principles AG
XETRA:T3T1
|
Germany | €12.81 Million |
|
Picton Property Income Ltd
LSE:PCTN
|
UK | GBX229.33 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Endonovo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1551.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Endonovo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Endonovo Therapeutics Inc (2010–2024)
The table below shows the annual total liabilities of Endonovo Therapeutics Inc from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $26.82 Million | +8.39% |
| 2023-12-31 | $24.75 Million | -26.05% |
| 2022-12-31 | $33.46 Million | +88.18% |
| 2021-12-31 | $17.78 Million | +4.72% |
| 2020-12-31 | $16.98 Million | -28.59% |
| 2019-12-31 | $23.78 Million | +52.09% |
| 2018-12-31 | $15.63 Million | +10.39% |
| 2017-12-31 | $14.16 Million | +59.48% |
| 2016-12-31 | $8.88 Million | +15.85% |
| 2015-12-31 | $7.67 Million | +61.77% |
| 2014-12-31 | $4.74 Million | +12.67% |
| 2013-12-31 | $4.21 Million | +114.66% |
| 2012-12-31 | $1.96 Million | +151427.92% |
| 2011-12-31 | $1.29K | -31.95% |
| 2010-12-31 | $1.90K | -- |